A new deep-learning system called Atomic Rotationally Equivariant Scorer (ARES) significantly improves the prediction of RNA structures over previous artificial intelligence (AI) models.
Stanford researchers have identified several peptides that inhibit the binding between certain nonstructural proteins of hepatitis C virus and cytoplasmic membranes.
Stanford researchers have discovered that amphipathic α-helical (AH) peptides that share an amino acid sequence homology to the N-terminus of HCV NS5A can rupture lipid vesicles in a size-dependent manner.
Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Researchers in Prof. Stephen Quake's laboratory have developed a CRISPER-Cas-based targeted endonuclease system designed to treat latent viral infections by attacking the viral genome.
The standard treatment for hepatitis C virus (HCV) is poorly tolerated and ineffective in a large subset of HCV patients. Scientists at Stanford and UCSF have developed new therapeutic leads for HCV that also have potential to be broad-spectrum anti-infectives.
Researchers in Prof. Mark Kay's laboratory have developed recombinant adeno-associated viral (AAV) capsid proteins that transduce human primary hepatocytes at high efficiency in vitro and in vivo.